



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/687,951	10/13/2000	Jeffrey I. Cleland	M-9177-US	8871

28442 7590 07/25/2002

BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, IL 60610

[REDACTED] EXAMINER

KAM, CHIH MIN

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1653

DATE MAILED: 07/25/2002

18

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application N .	Applicant(s)
	09/687,951	CLELAND ET AL.
Examiner	Art Unit	
Chih-Min Kam	1653	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 15 May 2002.

2a) This action is FINAL.                    2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 17 and 20-35 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 17 and 20-35 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some \* c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

1) Notice of References Cited (PTO-892)                    4) Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_ .

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)                    5) Notice of Informal Patent Application (PTO-152)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_ .                    6) Other: \_\_\_\_\_ .

## **DETAILED ACTION**

### ***Status of the Claims***

1. Claims 17 and 20-35 are pending.

Applicants' request for continued examination (Paper No. 16) and amendment filed on May 15, 2002 (Paper No. 17) are acknowledged. Claim 29 have been amended, and a new claim 35 has been added.

### **Objection Withdrawn**

2. The previous objection of claim 29 regarding the term "glucagons", is withdrawn in view of applicants' amendment to the claim.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claim 20 is rejected under 35 U.S.C. 112, first paragraph.

Claim 20 is rejected because the specification, while being enabling for a method for administering a biologically active agent comprising injecting the composition with particle size of 5-200 microns to a patient using a 23-gauge or smaller needle, does not reasonably provide enablement for a method for administering a biologically active agent comprising injecting the composition with particle size of < 1 mm using a 23-gauge or smaller needle. The specification does not enable a person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Claim 20 is drawn to a method for administering a biologically active agent comprising injecting the composition to a patient using a 23-gauge or smaller needle. The specification discloses microparticles used have a maximum dimension of < 1 mm (page 6, line 7), although the preferred microparticles have an average diameter of 5-200 microns (page 14, lines 4-5). The 23-gauge needle has an inside diameter of 0.318 mm (318  $\mu\text{m}$ , see page T679 of Aldrich catalog (2000-2001)), which is suitable for injection of the microparticles with particle size of < 200  $\mu\text{m}$  but not for all the particles having size of < 1 mm. Therefore, the claim needs to define the microparticle size as to the bore size of needle. The skilled artisan would require additional guidance in order to make and use such microparticles in a manner reasonably commensurate with the scope of the claims. Without such guidance, the experimentation left to those skilled in the art is undue.

The factors considered in determining whether undue experimentation is required, are summarized in In re Wands (858 F2d at 731,737, 8 USPQ2d at 1400,1404 (Fed. Cir.1988)). The factors most relevant to this rejection are the scope of the claims, the nature of the invention, and the amount of direction or guidance presented.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 21-34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite because the specification appears to define hyaluronic acid (see page 4, lines 21+) as part of or as a biologically active agent (see the definition proffered at page 6, lines 10+ of the current specification). Thus, claim 21 and claims dependent thereof are indefinite as to whether

hyaluronic acid is or is not part of an agent having in vivo activity, typically an activity that confers therapeutic, prophylactic, and/or diagnostic utility given the definition at page 4 of hyaluronic acid being found in the extracellular matrix of connective tissue. Thus, in claim 21, is item (a) included in item (b)(i) and/or (b) (ii)? For clarity, claim 28 should be cancelled in favor of inserting “polypeptide” in claim 21 in place of “agent”. Claims 22-34 are included in this rejection for being dependent on a rejected claim and not correcting the deficiency of the claim from which they depend.

5. Claim 20 recites the limitation "biologically active agent" in line 1 and "composition" in line 2. There is insufficient antecedent basis for this limitation in the claim.

6. Claim 24 is indefinite because of the use of the term "a copolymer comprising biodegradable and non-biodegradable units". Note that Markush groups must be closed and "a copolymer comprising biodegradable and non-biodegradable units" is open language in regard to the amounts of each in the copolymer which are not recited and make the copolymer undefined.

7. Claim 30, for example, is indefinite because claim 30 recites the limitation "the polymeric matrix comprising the biologically active agent" in line 2 of the claim. There is insufficient antecedent basis for this limitation in the claim. Claim 21 cites particles comprising a biologically active agent, and a biocompatible polymeric matrix. See also claim 31.

8. Claim 32 is indefinite because of the use of the term "derivative". The term "derivative" renders the claim indefinite, it is unclear what kind of ester derivative, amide derivative, lactide derivative, acyl derivative, polyethylene glycol derivative or water-insoluble derivative of hyaluronic acid is intended as compared to hyaluronic acid.

Art Unit: 1653

9. Claim 33 is indefinite because of the use of the term “amino acid modified hyaluronic acid”. The term “amino acid modified hyaluronic acid” renders the claim indefinite, it is unclear how hyaluronic acid, a sugar compound, would have amino acid modified.

10. Claims 29 and 35 are indefinite because the claim cites the terms “an anti-vascular endothelial growth factor Fab (anti-VEGF Fab)” and “an antibody”, it is unclear “anti-VEGF Fab” and “an antibody” are mutually exclusive since anti-VEGF Fab is an antibody.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

11. Claims 17, 20-28, 30-31 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Machida *et al.* (EP 0,263,490) in view of syringe section (page T679) of Aldrich catalog (2000-2001).

Machida *et al.* teach a sustained-release particulate preparation is obtained by mixing a biodegradable polymer (e.g., poly(lactic acid-glycolic acid), column 3; claims 24-27) in an organic solvent with a biologically active agent to form a solution, suspension or emulsion, and the mixture is then mixed with an aqueous solution comprising a natural high molecular weight of sugar such as hyaluronic acid (e.g., 1%, Example 1; claim 22) or sodium hyaluronate (column 3; claim 34) to prepare fine particles containing the biologically active agent such as granular colony stimulating-stimulating factor (column 3, lines 17-30; and Example 1 and 3; claims 17, 21 and 28). The particulate preparation has the concentration of copolymer ca. 240 or 500

mg/ml (Examples 1 and 3; claims 30 and 31) and has a particle size of 150 µm or less (column 2, line 8-13), which can be reconstituted with saline solution (column 10, claim 23) and is suitable for injection. However, Machida *et al.* does not disclose the type of syringe needle used for injection. The Aldrich catalog shows a 23-gauge syringe needle has an inside diameter of 0.318 mm (318 µm), which is suitable for injection of the particulate preparation with particle size of 150 µm or less (claim 20). At the time of invention was made, it would have been obvious to one of ordinary skill in the art to use the particulate preparation taught by Machida *et al.* using the copolymer of with a syringe of 23-gauge needle to administer a biologically active agent because one of ordinary skill in the art would have been motivated to check whether the particulate preparation containing the biologically active agent can be delivered with a smaller needle in order to improve the injectability of particulate preparation. Thus, the combined references result in the claimed invention and was, as a whole, *prima facie* obvious at the time the claimed invention was made.

***Conclusion***

12. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (703) 308-9437. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, Ph. D. can be reached on (703) 308-2923. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-0294 for regular communications and (703) 308-4227 for After Final communications.

Art Unit: 1653

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Chih-Min Kam, Ph. D. *CKK*  
Patent Examiner

\*\*\*

July 21, 2002

*Karen Cochrane Carlson, Ph.D.*  
KAREN COCHRANE CARLSON, PH.D.  
PRIMARY EXAMINER